Last checked at 14 Feb 2018 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
14 February 2018
Tekcapital plc
("Tekcapital" or the "Company")
Private Placement for Belluscura plc to raise US$1.33m
Tekcapital plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from university technology, is pleased to announce that Belluscura plc ("Belluscura") has concluded a private placement to raise approximately US$1.33m (the "Private Placement") through Dowgate Capital Stockbrokers and converted loans equal to approximately US$268k to equity under the same terms as the Private Placement.
This Private Placement was priced at US$0.18 (13p) per share, giving Belluscura a post-money valuation of approximately US$3.7m. Belluscura will extend the Private Placement for an additional 90 days to enable current shareholders and additional investors to participate.
Belluscura was established in the UK in December 2015 to provide premium proprietary medical devices at affordable prices. It has already launched three products with two more products in development. The proceeds of the Private Placement will be used for further investment in Belluscura's products in development, specifically the CURV™ oxygen concentrator and Snap III™ level of consciousness monitor and for general working capital purposes.
Commenting on the Private Placement, Bob Rauker, CEO of Belluscura, said: "We are very pleased to announce this Private Placement. The funds will allow Belluscura to continue with its mission to provide premium, proprietary medical devices at affordable prices."
Tekcapital has invested $250,000 in the Private Placement and converted loans to Belluscura of $210,090 to equity under the same terms as the Private Placement. As a result, Tekcapital's ownership interest in Belluscura is now 8,129,488 shares, representing approximately 39% of the issued share capital. Under the terms of the Private Placement, Tekcapital was issued with a three-year warrant to purchase 1,273,078 new shares in Belluscura at 13p per share.
For further information, please contact:
Tekcapital Plc |
|
Clifford M. Gross, Ph.D. | info@tekcapital.com |
Allenby Capital Limited (Nominated Adviser & Joint Broker) |
+44 (0) 20 3328 5656 |
Jeremy Porter / Alex Brearley |
|
|
|
Dowgate Capital Stockbrokers (Joint Broker) | +44 (0) 1293 517744 |
David Poutney / James Serjeant |
|
|
|
Walbrook PR Ltd | +44 (0) 20 7933 8780 |
Paul Cornelius / Helen Cresswell / Sam Allen | tekcapital@walbrookpr.com |
Tekcapital plc - The World's Largest University Network for Open Innovation
Tekcapital's objective is to create value from investing in new, university-developed intellectual properties. Additionally, using its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a range of IP investment services to make it easy for organisations to find, evaluate, acquire and license university-developed technology. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com
LEI: 213800GOJTOV19FIFZ85